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Previewswith energies of highest occupied
(HOMO) and lowest unoccupied (LUMO)
molecular orbital and electronegativities
of the involved chemical species (Suksri-
chavalit et al., 2008).
Do these findings imply that we need
to revisit our thinking about the mecha-
nism of action of at least some hydroxa-
mic based HDAC inhibitors, including
recently FDA-approved panobinostat
(LBH-589), and consider that they might
act also through HDAC-independent,
catalase mimetic mechanisms? One
important point to keep in mind about
Olson et al.’s study is that all of the cell
based assays were performed in the
presence of high concentrations of com-
pounds (usually 30 mM). These concentra-
tions might not be relevant from a clinical
perspective, given that, for example, in
the case of panobinostat, this concentra-
tion is >10,000 higher than the biochem-
ical IC50 calculated in vitro against
HDACs. By itself, this does not neces-
sarily mean that we should not think very
carefully about whether a systematic
re-evaluation of hydroxamic based
HDAC inhibitors and their HDAC-inde-432 Chemistry & Biology 22, April 23, 2015 ªpendent, catalase mimetic mechanisms
is needed. But we pose that the critical
question to keep in mind is whether the
high concentrations need to achieve
high catalase mimetic efficiency can be
reached in vivo in patients, for example,
in a chronic treatment setting. We think
that this is unlikely because dose-limiting
toxicity is readily achieved for all clinically
tested HDAC inhibitors at doses well
below the ‘‘catalase mimetic’’ range
(Figure 1). For panobinostat, clinically
used doses reachmaximum values below
1 mM (Anne et al., 2013). Interestingly,
Olson et al. (2015) suggest that HDAC
inhibitors may act through a dual mecha-
nism against oxidative stress: (1) inhibition
of HDACs at low concentrations and (2)
catalase mimetics at high concentrations.
On the other hand, we think that the
only clinically relevant concentrations for
HDAC inhibitors are the ‘‘low’’ ones and
that catalase mimetic mechanism might
be of importance for those interested in
exploring effects of HDAC inhibitors and
oxidative stress in cell-based settings.
The work by Olson et al. (2015) opens up
several interesting opportunities for future2015 Elsevier Ltd All rights reservedresearch. For example, it might be inter-
esting to design new hydroxamic-acid-
based compounds that would exhibit
catalase mimetic activity at much lower
concentrations. Those compounds would
be more clinically attractive strategy to
protect from oxidative stress via HDAC-
dependent and -independent routes.
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The inflammatory response is a critical component of the immune system that is activated by stimuli such as
cytokines, foreign DNA, RNA, or other harmful substances. Krukenberg et al. (2015) identify poly(ADP-ribose)
as a new signaling molecule that activates inflammation, thus providing yet another mechanism by which
PARPs are involved in cellular stress responses.Multicellular organisms are in constant
danger from harmful foreign substances,
chemicals, and pathogens. Multiple
defense mechanisms have therefore
evolved to counter these threats. In mam-
mals, the innate immune system acts
as the front line defense to detect these
stimuli and to mount an initial response
that puts the immune system into a state
of alert (Janeway and Medzhitov, 2002).Stimuli such as foreign DNA, RNA, or
other harmful substances are detected
by macrophages that are subsequently
activated. Upon activation, the macro-
phages secret cytokines that attract im-
mune cells to the site of danger, activate
immune cells, and present them with the
molecular signature of the threat. Stimuli
that activate macrophages are called
PAMP (pathogen-associated molecularpattern) when derived from pathogens
(e.g., DNA, RNA, or other molecules) or
DAMP (damage-associated molecular
pattern) during noninfectious inflamma-
tory responses (e.g., harmful substances
or normally intracellular host DNA, RNA,
or proteins) (Tang et al., 2012). These sig-
nals are primarily recognized by pattern
recognition receptors (PRR) such as
members of the toll-like receptor (TLR)
Figure 1. PARP1 Enzymatic Activity Is Highly Upregulated in Cells
Undergoing Necrosis
Upon lysis of the necrotic cell, the PAR synthesized by PARP1 is released into
the extracellular space. Extracellular PAR can then be detected by TLR2 and
TLR4, which are endocytosed and signal the activation of NFkB, resulting in
the secretion of cytokines and activation of an inflammatory response.
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Previewsfamily found at the plasma
membrane and intracellular
membranes or the NOD-like
(NLRs) and RIG-I-like recep-
tors (RLR) found in the cyto-
plasm. Upon engagement of
these receptors, signaling
cascades are induced that
culminate in the activation of
multiple stress-response
pathways. The key pathway
activated is NFkB, leading to
increased transcription and
subsequent release of inflam-
matory cytokines.
Poly(ADP-ribose) (PAR) is a
posttranslational modification
generated by poly(ADP)ribose
polymerases (PARPs) using
NAD+ as a substrate (Gibsonand Kraus, 2012). Most PARPs modify
target proteins with monomers called
mono(ADP-ribose); however, several
PARPs, including PARP1, 2, 5a, and 5b,
are capable of generating PAR polymers.
In addition to modifying target protein
function by covalent attachment, PAR
can also act as a signaling molecule by
recruiting PAR binding proteins. Through
this signaling function, PAR can alter
the localization, binding interactions,
or activity of target proteins. PAR is
primarily known to function in stress
responses, but also plays stress-inde-
pendent roles, in which it influences gene
expression and signal transduction (Vyas
and Chang, 2014). PARP1 in particular
has been shown tomodulate transcription
of a subset of NFkB target genes during
inflammation (Altmeyer and Hottiger,
2009).
To date, all of the functions identified
for PAR as a signaling molecule occur
intracellularly. Krukenberg et al. (2015)
now show that PAR can act as an
extracellular signaling molecule that is
endocytosed into endosomes by macro-
phages, activating NFkB signaling. This
process requires the PRRs TLR2 and
TLR4, which can detect variousmolecules
including thebacterial cell wall component
lipopolysaccharide (LPS). Upon PAR
binding, TLR2 and TLR4 induce an in-
flammatory response in a manner similar
to pathogenic DNA and RNA (Akira and
Takeda, 2004). This new pathway of in-
flammatory response activation is specific
to PAR, since single units of ADP-ribose
or structurally similar molecules cannotinduce this response. Therefore PAR can
becategorizedasanovelDAMP(Figure1).
The current study (Krukenberg et al.,
2015) has not identified the source of the
extracellular PAR that activates macro-
phages. One possible source is cells un-
dergoing necrosis, a form of uncontrolled
cell death known to induce an inflamma-
tory response. PARP1 is hyperactivated
during necrotic cell death, resulting in
increased synthesis of PAR and a
corresponding depletion of NAD+ and
ATP (Zong et al., 2004). Following necrotic
lysis, the dying cells release high levels of
PAR, which can then be detected by
macrophages as described in the present
study (Figure 1). Therefore, PAR could act
as a signal for macrophages to engage
the immune system at the site of necrosis.
Other possibilities include the detection of
stressed cells that could act as a signal
that engagement of the immune system
is needed. These cells could actively
secrete PAR, or PARylated proteins in
a yet unidentified manner as a means to
activate macrophages. Whether TLRs
directly recognize, bind to, or endocytose
PAR has not been investigated, but it is
an area of obvious interest given these
results. TLRs require additional molecules
(for instance CD14 in the case of LPS
[Zanoni et al., 2011]) to detect their
targets, so the possibility exists that PAR
also requires additional factors to be
detected by TLRs.
Given thewidespread function of inflam-
mation in pathologies, the results fromKru-
kenberg et al. (2015) could have important
clinical relevance. Once identified, acti-Chemistry & Biology 22, April 23, 2015 ª2015 Elsevating the PARP(s) that
are relevant in this new inflam-
matory signaling pathway or
systemic infusionofPARcould
be used to enhance the
immuneresponsebyproviding
an additional signal for activa-
tion of the immune system. It
is already established that
PARP1 inhibitors have an
anti-inflammatory effect as a
result of regulation of tran-
scription (Peralta-Leal et al.,
2009). These inhibitors could
also impinge upon this extra-
cellular mechanism of eliciting
an inflammatory response.
Such inhibition could help
dampen the immune response
by preventing activation ofmacrophages by the released PAR and
the following induction of proinflammatory
cytokines. Modulation of this response
could therefore be an interesting avenue
for follow-up studies and the treatment of
conditions of hyperactive inflammation.
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